丹奥治疗急性颈动脉系统缺血性脑卒中的临床研究

目的 观察丹奥治疗急性颈内动脉系统缺血性脑卒中的临床疗效及安全性。方法本研究选用发病72h内急性颈内动脉系统脑梗死患者100例,随机分为治疗组和对照组。治疗组给予丹奥和银杏叶静脉输注,对照组仅给予银杏叶静脉输注。比较两组治疗前和治疗14d的NIHSS评分、BI指数、血小板聚集率、FIB和INR值及不良反应发生率,评价丹奥的疗效和安全性。结果治疗14d时丹奥治疗组NIHSS评分为（3．80±3．64）分,BI值为（83．80±9．23）,血小板聚集率为（41．92±3．35）％,INR值为（1．094±0．843）,FIB值为（3．45±0．33）g／L;而对照组NIHSS评分为（6．64±4．89）分,BI值为（75．6±1．90）,血小板聚集率为（49．86±5．72）％,INR值为（1．003±0．090）,FIB值为（3．77±0．28）g/L。两组资料比较差异均有统计学意义（P〈0．01）。两组患者在肝肾功能的异常、血小板数量、过敏现象、脑出血、消化道出血的出现比例上无统计学意义。结论丹奥是一种安全有效的治疗急性颈内动脉系统脑梗死的药物。

Ozagrel in the treatment of patients with acute carotid artery system ischemic stroke

Objective To discuss the efficacy and safety of ozagrel on acute carotid artery system ischemic stroke. Methods 100 cases with acute carotid artery system ischemic stroke within 72 hours after onset were enrolled in this study consecutively, and were divided into two groups randomly, the cases in ozagrel treated group were received ozagrel intravenous infusion associated with ginkgo biloba leaf extract treatment and the cases in control group were only treated with ginkgo biloba leaf extract. The NIHSS scores, BI index, the levels of plasma platelet aggregation ratios, INR and FIB in the two groups before and 14 days after treatment were assayed, the therapeutic effects of ozagrel were evaluated. Results After 14 days treatment, the average NIHSS score, BI index, plasma platelet aggregation ratio, INR value and FIB level were 3.80 ± 3.64 and 6.64±4.89, 83.80 ±9.23 and 75.6 ±1.90, 41.92 ± 3.35 and 49.86 ± 5.72, 1. 094 ± 0.843 and 1. 003± 0. 090, 3.45 ± 0.33 and 3.77 ±0.28 in ozagrel treated group control group, respectively. All the data between two groups have statistical significance （ all P 〈 0.01 ）. The levels of plasma ALT/GGT, BUN/Cr, platelet counts, and the ratios of allergy, cerebral hemorrhage and gastrointestinal bleeding in the two groups have not statistical significance. Conclusion Ozagrel is one of the effective and safe agents to treat acute carotid artery ischemic stroke.